Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Common Equity (2019 - 2025)

AVITA Medical's Common Equity history spans 7 years, with the latest figure at -$16.6 million for Q4 2025.

  • For Q4 2025, Common Equity fell 470.08% year-over-year to -$16.6 million; the TTM value through Dec 2025 reached -$16.6 million, down 470.08%, while the annual FY2025 figure was -$16.6 million, 470.08% down from the prior year.
  • Common Equity reached -$16.6 million in Q4 2025 per RCEL's latest filing, down from -$6.7 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $118.9 million in Q1 2021 to a low of -$16.6 million in Q4 2025.
  • Average Common Equity over 5 years is $55.2 million, with a median of $65.8 million recorded in 2023.
  • Peak YoY movement for Common Equity: skyrocketed 75.55% in 2021, then tumbled 470.08% in 2025.
  • A 5-year view of Common Equity shows it stood at $104.6 million in 2021, then decreased by 19.01% to $84.7 million in 2022, then tumbled by 42.11% to $49.1 million in 2023, then plummeted by 90.83% to $4.5 million in 2024, then crashed by 470.08% to -$16.6 million in 2025.
  • Per Business Quant, the three most recent readings for RCEL's Common Equity are -$16.6 million (Q4 2025), -$6.7 million (Q3 2025), and -$12.9 million (Q2 2025).